Literature DB >> 18781681

Treatment of levodopa-induced motor complications.

Fabrizio Stocchi1, Michele Tagliati, C Warren Olanow.   

Abstract

Chronic levodopa treatment for Parkinson's disease patients is frequently associated with the development of motor complications such as end-of-dose wearing-off and dyskinesias. In this review, we provide an overview of the strategies available for dealing with these problems. Medical management includes manipulation of levodopa dosing to establish the optimum treatment schedule, improving levodopa absorption, catechol-O-methyl transferase-inhibition (COMT), Monoamine oxidase-B (MAO-B) inhibition, dopaminergic agonists, amantadine, and continuous dopaminergic infusions. Surgical procedures and particularly deep brain stimulation are also reviewed. It should be noted that none of these treatments has been shown to provide anti-parkinsonian efficacy that is greater than what can be achieved with levodopa. We highlight the importance of initiating therapy with a treatment strategy that reduces the risk that a Parkinson's disease patient will develop motor complications in the first place. Key Words: Advanced PD, dyskinesias, motor fluctuations, levodopa, dopamine agonists, COMT inhibitors, MAO-B inhibitors. (c) 2008 Movement Disorder Society.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18781681     DOI: 10.1002/mds.22052

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  26 in total

Review 1.  Targeting nicotinic receptors for Parkinson's disease therapy.

Authors:  Maryka Quik; Tanuja Bordia; Luping Huang; Xiomara Perez
Journal:  CNS Neurol Disord Drug Targets       Date:  2011-09-01       Impact factor: 4.388

2.  Ceftriaxone reduces L-dopa-induced dyskinesia severity in 6-hydroxydopamine parkinson's disease model.

Authors:  Tanya Chotibut; Samantha Meadows; Ella A Kasanga; Tamara McInnis; Mark A Cantu; Christopher Bishop; Michael F Salvatore
Journal:  Mov Disord       Date:  2017-06-20       Impact factor: 10.338

Review 3.  Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation.

Authors:  Mahmoud M Iravani; Peter Jenner
Journal:  J Neural Transm (Vienna)       Date:  2011-09-01       Impact factor: 3.575

4.  3-Dimensional hollow graphene balls for voltammetric sensing of levodopa in the presence of uric acid.

Authors:  Xin Gao; Hongyan Yue; Shanshan Song; Shuo Huang; Bing Li; Xuanyu Lin; Erjun Guo; Bao Wang; Enhao Guan; Hongjie Zhang; Pengfei Wu
Journal:  Mikrochim Acta       Date:  2018-01-10       Impact factor: 5.833

5.  Inhibition of Ras-guanine nucleotide-releasing factor 1 (Ras-GRF1) signaling in the striatum reverts motor symptoms associated with L-dopa-induced dyskinesia.

Authors:  Stefania Fasano; Erwan Bezard; Angela D'Antoni; Veronica Francardo; Marzia Indrigo; Li Qin; Sandra Doveró; Milica Cerovic; M Angela Cenci; Riccardo Brambilla
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-29       Impact factor: 11.205

Review 6.  Catechol-O-methyltransferase inhibitors in Parkinson's disease.

Authors:  Thomas Müller
Journal:  Drugs       Date:  2015-02       Impact factor: 9.546

7.  L-Dihydroxyphenylalanine modulates the steady-state expression of mouse striatal tyrosine hydroxylase, aromatic L-amino acid decarboxylase, dopamine and its metabolites in an MPTP mouse model of Parkinson's disease.

Authors:  Jennifer M King; Gladson Muthian; Veronica Mackey; Marquitta Smith; Clivel Charlton
Journal:  Life Sci       Date:  2011-08-18       Impact factor: 5.037

Review 8.  Dopaminergic therapy and subthalamic stimulation in Parkinson's disease: a review of 5-year reports.

Authors:  Luigi M Romito; Alberto Albanese
Journal:  J Neurol       Date:  2010-11       Impact factor: 4.849

Review 9.  Continuous drug delivery in Parkinson's disease.

Authors:  Marina Senek; Dag Nyholm
Journal:  CNS Drugs       Date:  2014-01       Impact factor: 5.749

Review 10.  Continuous intestinal infusion of levodopa/carbidopa in advanced Parkinson's disease: efficacy, safety and patient selection.

Authors:  Giovanni Abbruzzese; Paolo Barone; Ubaldo Bonuccelli; Leonardo Lopiano; Angelo Antonini
Journal:  Funct Neurol       Date:  2012 Jul-Sep
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.